Objective: HIV-infected women are burdened by depression and anxiety, which may impact adherence to antiretroviral therapy and overall quality of life. Yet, little is known about the scope of psychological symptoms in the growing number of HIV-infected women reaching menopause, when affective symptoms are more prevalent in the general population. We conducted a longitudinal study to compare affective symptoms between perimenopausal HIV-infected and non-HIV-infected women.
M ore women with HIV are reaching midlife and experiencing menopause than ever before, as the proportion of older women with HIV in the United States has more than tripled in the past decade. 1 The psychological symptoms of menopause warrant investigation among the growing population of HIV-infected women, many of whom are disproportionately burdened by depression and anxiety in their earlier adult life. [2] [3] [4] A recent mixed cohort study of HIV-infected and non-HIV-infected women found that depressive symptoms were elevated among all women in early perimenopause, and depressive symptoms associated with nonadherence to antiretroviral therapy among the HIVinfected women. 5 Thus, an understanding of the affective symptoms of midlife HIV-infected women is essential to optimize the health of this population, and develop strategies to support adherence to HIV clinical care.
Women are susceptible to both mood and anxiety symptoms at midlife. Indeed, increased risk for the development of depressive symptoms has been observed during the menopause transition, particularly among women with a history of minor or major depressive disorder. 6, 7 Prior large cohort studies of non-HIV-infected women have determined that perimenopausal women are at three times greater risk of experiencing depressive symptoms compared with premenopausal women. 8 Similarly, anxiety symptoms are also more prevalent among women at midlife, even among women who have low levels of anxiety before the menopause transition. 9 In non-HIV-infected women, the etiology of depressive symptoms and anxiety in relation to the menopause transition is multifactorial, and has been attributed to hormonal changes, vasomotor symptoms, sleep disturbance, and stressful life events. [10] [11] [12] We have shown previously that perimenopausal HIV-infected women experience greater hot flash severity and hot flash-related interference with daily function compared with perimenopausal non-HIV-infected women. 13 Bothersome hot flashes may influence the development or existing state of depression or anxiety in women with HIV, though this remains largely unexplored in this population. This paucity of research has negative implications on the clinical evaluation and treatment of depression and anxiety in the growing population of HIV-infected women at midlife, and the potential for broader implications on promoting health for this population, such as adherence to HIV clinical care.
This longitudinal study was designed to prospectively evaluate affective symptoms in a cohort of perimenopausal women with and without HIV, over a period of 12 months. We hypothesized that depression and anxiety scores would be higher among HIV-infected women at baseline and would remain stable and elevated over 12 months, compared with the symptom levels in the non-HIV-infected women. As an extension of our prior cross-sectional analysis, 13 we also evaluated longitudinal differences in menopause symptom severity and hot flash-related daily interference in this cohort. We hypothesized that menopause symptoms and hot flashrelated daily interference, previously reported to be more severe in perimenopausal HIV-infected women relative to perimenopausal non-HIV-infected women, 13 would continue to remain elevated in the HIV-infected women at 12 months. The relationship between hot flash characteristics and depression and anxiety scores was evaluated to examine the potential association of affective symptom burden with vasomotor symptom levels.
METHODS

Participants
A cross-sectional investigation of hot flash severity and hot flash-related interference with daily function was previously published among this cohort of 66 perimenopausal women with and without HIV (33 HIV-infected and 33 non-HIVinfected women). 13 The current study evaluates the 12-month longitudinal data on depression, anxiety, and menopause symptoms in the same cohort. Eligibility criteria were previously described. 13 Briefly, women were between the ages of 45 and 52 years, and perimenopause status was classified as presence of 1 menstrual cycle greater than 60 days in length in the past 6 months, or irregular menses in 2 or more menstrual cycles in the past 6 months.
14 Women were not eligible if they were amenorrheic for 12 months or longer, had a hysterectomy, had active cancer, had used hormone therapy in the past 6 months, or were pregnant or breastfeeding. Women with HIV were required to be on a stable HIV treatment regimen for at least 3 months before study enrollment and did not experience an opportunistic infection during this period. Women were recruited for the study by posting flyers and newspaper ads at HIV community organizations and outpatient clinics. A hospital-based research participant data registry that includes patients interested in learning about research studies also served as a recruitment method. Participants received $100 for participation. A stratification algorithm 13 was used to recruit women without HIV who were similar in age, race, and menstrual patterns to the women with HIV. Careful attention was also paid to matching participants on body mass index (BMI). This study was reviewed and approved by the Partners Healthcare institutional review board, Boston, MA.
Data collection
The primary data were collected at baseline and 12 months. At each time point, depression, anxiety, and menopause symptoms were assessed using standardized self-reported measures, and data on general and HIV-related health, and medication usage (including current use of antidepressants and anxiolytics) were obtained. Participants were also asked if they had ever been diagnosed with depression or anxiety by a professional. Menstrual bleeding frequency over the prior 6 months was re-assessed at a brief 6-month assessment and again at the 12-month visit. Twenty-seven HIV-infected women and 30 HIV-negative women had menstrual history data available at the 6 and the 12-month visit. At baseline, women were also asked to report number of days with hot flashes in the past month. Baseline estradiol and folliclestimulating hormone (FSH) were measured via Access 7) and HIV viral load levels (n ¼ 11), due to poor venous access or insufficient blood collection volume.
Questionnaires
Mood symptoms
Depressive symptoms were assessed with the Center for Epidemiologic Studies Depression Scale (CES-D), a 20-item scale used widely to assess depressive symptom severity. 15 Participants were asked to describe frequency of each depressive symptom component experienced during the past week (rarely or none of the time; some or little of the time; occasionally or a moderate amount of the time; most of the time). Total scores range from 0 to 60, with higher scores indicating greater symptomatology. A total CES-D score greater than or equal to 16 indicates depressed mood and increased risk for clinical depression. 16 The Generalized Anxiety Disorder 7-item scale (GAD-7) was completed to measure symptoms of anxiety. 17 Participants were asked to describe how frequently they were bothered by specific anxiety symptoms over the past 2 weeks. Item responses range from 0 to 3 (not at all, several days, more than half the days, nearly every day), and total scores range from 0 to 21, with higher scores indicative of greater anxiety (0-4 indicates minimal anxiety, 5-9 indicates mild anxiety, 10-14 indicates moderate anxiety, 15-21 indicates severe anxiety). 17 
Menopause symptoms
The Menopause Rating Scale (MRS) was used to measure presence and severity of menopause symptoms experienced ''at this time.'' The item response scale for each of the questions ranges from 0 to 4 (none, mild, moderate, severe, extremely severe), with total MRS scores ranging from 0 or asymptomatic, to 44 or highest degree of complaint. 18, 19 Item 1 of the MRS was used to determine hot flash severity. The Hot Flash Related Daily Interference Scale (HFRDIS) was used to evaluate the impact of hot flashes on daily activities and quality of life during the past week. The item response for each of the 10 questions ranges from 0 (do not interfere) to 10 (completely interfere), with the total HFRDIS score ranging from 0 to 100 (higher score represents greater interference). 20 
Statistical analysis
The Shapiro-Wilk test was used to assess normality of the study variables. Normally distributed data were summarized as mean AE standard deviation (SD), and non-normally distributed data were reported as median (interquartile range [IQR] ).
Student's t tests were performed to compare differences in normally distributed outcomes between the HIV-infected and non-HIV-infected women; non-normally distributed data were compared by the Wilcoxon rank-sum test. Categorical variables were compared using the chi-square test and are presented as percentages/numbers. Within-group (HIV and non-HIV-infected women) changes in symptom scores over 12 months were compared using paired t tests, and betweengroup comparisons of within-group change from baseline to 12 months were analyzed using the Student's t test or Wilcoxon rank-sum test. Linear regression models were created to estimate the relationship between the dependent variables (baseline CES-D score and GAD-7 score) and explanatory variables at baseline, and 95% confidence intervals (CIs) about estimated effects were computed. First, univariable models were created for the CES-D score and the GAD-7 score, controlling for HIV status. Next, multiple regression modeling was performed for the CES-D score and separately for the GAD-7 score. Both models adjusted for explanatory variables that differed between the HIV and non-HIV groups, including current smoking status, substance abuse history, and current use of antidepressant medication. A separate set of purposeful models were also generated to evaluate the association between hot flash characteristics and baseline CES-D and GAD-7 scores in the study sample. Both models adjusted for vasomotor symptom characteristics including number of days with hot flashes in the past month and hot flash severity (MRS item 1), respectively. Smoking status was added to this model as it is known to influence hot flashes. 21 For the purpose of this analysis, MRS item 1 was dichotomized (presence of moderate, severe, or extremely severe hot flashes vs none or mild hot flashes), and post hoc analyses were conducted to determine equal distribution among this dichotomized hot flash severity variable (n ¼ 66; 31 [47%] reported none or mild hot flashes; n ¼ 35 [53%] reported moderate, severe, or extremely severe hot flashes). Collinearity was assessed in each model by performing backwards/forwards selection of each covariate with HIV status, and the overall parameter estimate for HIV status remained generally stable within all models. Assumptions of linear regression in all models were also assessed using graphical methods including quantile-quantile and variance plots.
In a subgroup analysis among HIV-infected women only, univariable models were created in parallel for the GAD-7 and CES-D scores measured at baseline, and HIV-specific characteristics including duration of HIV (years) and current antiretroviral therapy use. HIV viral load and CD4 count were not included in these models due to a high proportion of the study sample having missing data on these HIV disease status markers.
This investigation among 66 women had power to detect a 0.7 SD difference between the groups, with statistical power of 0.8 and a two-sided 0.05 significance level. 13 Analyses were conducted with SAS JMP statistics software (version 12; SAS Institute Inc., Cary, NC).
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RESULTS
Study participants
Baseline characteristics of the 66 women (33 HIV-infected and 33 non-HIV-infected) are presented in Table 1 . As described previously, 13 the groups did not differ in age, race, or menstrual patterns, and the mean duration of HIV was 14 AE 6 years. Most women remained perimenopausal throughout the study, with only 3 (10%) of the non-HIVinfected women and 5 (19%) of the HIV-infected women with available data reporting not having any menstrual periods during the 12-month follow-up (P ¼ 0.36). Significant differences were not observed regarding history of a diagnosis of anxiety or depression, or current use of anxiolytics at baseline. However, a greater number of HIV-infected women reported current antidepressant use (48% vs 18%; P ¼ 0.009).
Affective and hot flash symptoms at baseline
The HIV-infected women had significantly higher CES-D scores that were nearly twice as high as the non-HIV-infected women (median 21 [IQR 12, 29] vs 10 [5, 14] ; P ¼ 0.0006). Similarly, the proportion of HIV-infected women with CES-D scores !16 was substantially greater than non-HIV-infected women (67% vs 21%; P ¼ 0.0002; Table 2 ), suggesting the possibility of a higher prevalence of clinical depression.
In addition, the HIV-infected women had higher GAD-7 scores (7 [5, 15] , indicating mild anxiety), compared with non-HIV-infected women (2 [1, 7] , reflecting minimal anxiety; P ¼ 0.0003; Table 2 ).
Data showing higher menopause symptom questionnaire scores (MRS and HFRDIS) at baseline in the HIV than the non-HIV women are presented in Table 2 , and were previously published. 13 Sixty-seven per cent (22) of the HIV-infected women compared with 42% (14) of the non-HIV-infected women reported having a greater number of days with hot flashes in the past month (hot flashes 8 or more days [median split] in the past month at baseline; P ¼ 0.048). 13 Affective symptoms at 12 months and longitudinal changes from baseline to 12 months Two HIV-infected women and 1 non-HIV-infected woman were lost to follow-up at 12 months. Both of the affective symptoms questionnaire scores (CES-D, GAD-7), and also the menopause symptoms questionnaire scores (MRS, HFRDIS) remained significantly higher in the HIV-infected women versus the non-HIV-infected women at 12 months (P < 0.01 for all variables; Table 2 , Fig. 1 ), whereas the hot flash severity (MRS item 1) score showed a statistical trend (P ¼ 0.09) toward a higher score in the HIV group at 12 months. The total scores for each questionnaire and MRS item 1 remained generally stable from baseline to 12 months, without significant differences in questionnaire scores between or within each group over the 12-month period (HIV-infected vs non-HIV-infected; P > 0.05 for all analyses; Table 2 ). The proportion of individuals with CES-D scores indicative of clinical depression was not statistically different between groups at 12 months (61% vs 41%; P ¼ 0.10).
Predictors of affective symptoms at baseline
In univariable linear regression models, HIV-infected women were estimated to have baseline mean CES-D scores 4.8 points higher than the non-HIV-infected women (P ¼ 0.0004), and mean GAD-7 scores 2.5 points higher than non-HIV-infected women (P ¼ 0.0003), reflecting higher levels of depressive and anxiety symptoms, respectively (Tables 3 and 4) . After controlling for current smoking status, history of substance abuse, and current antidepressant use, HIV-infected women were still estimated to have a mean CES-D score 3.0 points higher than the non-HIV-infected women (P ¼ 0.03), and a mean GAD-7 score 1.9 points higher than non-HIV-infected women (P ¼ 0.01) (Tables 3 and 4) .
The purposeful multivariable models (Tables 5 and 6 ) adjusted for HIV status, hot flash severity, number of days with hot flashes in the past month, and smoking. Three covariates were identified to have independent, significant associations with baseline CES-D scores. HIV-infected women were estimated to have a 3.0 point higher mean CES-D score compared with non-HIV-infected women (P ¼ 0.02). Women with moderate, severe, or extreme severe hot flash severity were estimated to have mean CES-D scores 3.1 points higher than women who reported none or mild hot flash severity (P ¼ 0.048), and current smokers were estimated to have mean CES-D scores 3.1 points higher than nonsmokers (P ¼ 0.02). HIV-infected women were estimated to have mean GAD-7 scores that were 1.7 points higher than non-HIV-infected women (P ¼ 0.01), and women with moderate, severe, or extremely severe hot flash severity were estimated to have mean anxiety symptom scores that were 1.9 points higher than women who reported none or mild hot flash severity (P ¼ 0.02).
Predictors of affective symptoms at baseline in HIVinfected subgroup
In the univariable models for baseline GAD-7 scores among the HIV-infected women, a significant relationship was observed between duration of HIV and GAD-7 scores, with mean GAD scores decreasing by an estimated 3.9 points 
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for women living 10 years longer with HIV (P ¼ 0.02). A significant association between GAD-7 scores and current antiretroviral therapy use was not observed, nor were significant univariable associations between duration of HIV or current antiretroviral therapy use and CES-D scores observed (P > 0.05). DISCUSSION To our knowledge, this study represents the first longitudinal analysis reporting differences in affective and menopause symptoms between perimenopausal women with and without HIV of similar race, BMI, menstrual patterns, and age. Our findings demonstrate that HIV-infected women, with relatively stable HIV infection, have greater depressive and anxiety symptoms compared with non-HIV-infected women, and these symptom levels remain significantly elevated compared with non-HIV-infected women after 1 year of follow-up. Significant differences in symptom scores between or within each group over the 12-month period were not observed in our cohort. The between-group differences in mood and anxiety symptoms at baseline remained significant when controlling for factors that differed between the groups including smoking status, substance abuse history, and antidepressant use. Furthermore, an association of hot flash severity, and both depression and anxiety scores was observed. Collectively, these findings illustrate that HIV-infected women experience a disproportionate burden of affective symptoms at midlife, which persist during the perimenopause transition. Such symptoms, particularly depression and anxiety, have important clinical implications for the growing number of women aging with HIV, because of their impact on quality of life, HIV treatment adherence, and resulting mortality. 3, 22, 23 Depression is the most robust predictor of nonadherence to antiretroviral therapy, 24 and has also been implicated in failure to be retained in HIV care. 25 Failure to maintain viral load suppression is associated with increased morbidity and mortality, and also increased risk of HIV transmission. 26 However, effective depression interventions exist, some of which directly 
ASSOCIATION BETWEEN HIV STATUS AND MOOD
target adherence to antiretroviral therapy. 27 Our findings highlight the need for careful assessment of depressive symptoms in HIV-infected women during perimenopause, when the risk for depressive symptoms is elevated, particularly among those with a known history of depression.
The overall estimated prevalence of current depression based on the established CES-D threshold score in both groups of our study cohort exceeds the national average of 12.3% for women age 40 to 59 years, 28 and is notably greater than previous reports of 19.4% 4 and 25.8% 3 among women living with HIV in their mid-to-late thirties (ie, younger than average age of perimenopause). The proposed relationship between HIV and depression in our sample of perimenopausal women is unlikely due to age alone, as depressive symptoms tend to remain stable or decline with increasing age in both the general population and in HIV-infected populations. 29 At least among the women living with HIV, this may be an artifact of the increased stressors known to impact persons living with HIV, such as poverty, unstable housing, and abuse histories. Further, the influence of HIV disease burden was unlikely to have influenced CES-D scores, as 77% of the HIVinfected women had stable HIV infection, indicated by undetectable HIV viral load levels. Based on our findings, a greater hot flash burden and other psychosocial factors associated with midlife and the perimenopause may also result in more psychological distress.
Our observed association between hot flashes and depressive symptoms is similar to findings from the study by Maki et al, 5 which determined that vasomotor symptoms predicted elevated depressive symptoms in both HIV-infected and non-HIV-infected women. Our HIV-infected women reported greater hot flash severity compared with the non-HIVinfected women at both baseline and at 12 months. This finding suggests that hot flash severity may serve as a sexspecific contributor to depressive symptoms among HIVinfected women during the menopause transition. As such, assessment and treatment of hot flashes among HIV-infected women at midlife is encouraged to reduce this burdensome symptom and its potential influence on depressive symptoms in this population.
It is notable that the prevalence of depressive symptoms in the sample was elevated, despite the fact that nearly half of the HIV-infected women reported current use of antidepressant medications. While antidepressant dosing information was not determined, this observation suggests that HIV-infected women may be suboptimally treated for their depressive symptoms, consistent with a report by Mello et al, 3 who found that only 23% of currently depressed, HIV-infected women were receiving antidepressants. This may reflect a lack of or ineffective depression screening practices in the places where HIV-infected women seek care, or reduced adherence to psychiatric medications. A more recent study documented disparities in antidepressant treatment among individuals living with HIV by sex, whereas women with HIV are more likely than HIV-infected men to receive antidepressant treatment, they demonstrate substantial drop-off along the depression treatment cascade that may result in suboptimal treatment. 30 Establishing effective means by which to identify and treat depression in the settings in which older, HIV-infected women are likely to seek health care is critical to optimize overall quality of life and to support adherence to life-saving antiretroviral therapy.
HIV-infected participants in the present study also reported worse anxiety symptoms than women without HIV, both at baseline and 1 year, though the clinical relevance of these between-group differences (eg, the difference between mild to minimal anxiety symptoms) is less clear as anxiety symptoms were in the mild range among the HIV-infected group. Anxiety disorders are prevalent among HIV-infected individuals, with studies utilizing structured interviews documenting rates of approximately 11% to 12%. 4, 31 Low rates of anxiety in the sample may be explained by the anxiety scale used that reflects symptoms specific to generalized anxiety, and thus may have failed to capture the full range of symptoms characterizing the broader group of recognized anxiety symptoms pertinent to this population. A significant relationship between length of time living with HIV (mean duration of HIV in this cohort was 14 AE 6 years) and anxiety was also observed, such that women living with HIV for longer periods of time reported lower levels of anxiety. Existing qualitative data suggest this may be a result of increased mastery of managing an HIV diagnosis, and also decreased worry about immediate survival. 32 Thus, assessment of anxiety symptoms among women newly diagnosed with HIV at midlife, during perimenopause, may be critical given the potential for the cumulative effects of hormonal changes and a new HIV diagnosis on anxiety symptom burden.
Smoking has been associated with depression in HIVinfected individuals. 33 In the current study, smoking, in addition to HIV infection and hot flash severity, was independently associated with depressive symptoms. Furthermore, among non-HIV-infected women, current or past smoking has been frequently associated with presence and severity of hot flashes, and also hot flash severity. 21 Seventy per cent of the HIV-infected women were smokers in our study, which is consistent with previous literature documenting increased smoking rates among HIV-infected individuals compared with non-HIV-infected individuals. [34] [35] [36] [37] Similarly, substance abuse is common among individuals with HIV, 38 and 76% of the HIV-infected women in our cohort reported a history of substance abuse. Substance abuse history has been linked to nonuse of antiretroviral medications. 39 Together with depressive symptoms, a history of substance abuse makes this population of women particularly at risk for adverse outcomes. Indeed, providing education on the deleterious effects of cigarette smoking and substance abuse on physical and mental health to women at midlife is an important strategy to improve wellness in this population.
Although the longitudinal nature of this investigation and study cohort enhanced the validity of the study findings, generalizability may be limited due to the small sample size. Further, this was a clinical population with prespecified LOOBY ET AL eligibility criteria versus a community-based epidemiology study; thus, study findings may be limited by selection bias. Missing data existed for some of the HIV clinical variables including HIV viral load and CD4 count due to poor venous access that limited blood collection. Thus, models assessing the relationship between HIV-specific clinical variables and mood symptoms could not be fully evaluated. Data on ''current'' substance abuse were not collected. Thus, the relationship between current substance abuse and hot flashes could not be evaluated in the multivariable models. Findings from this current study of perimenopausal women with HIV support further evaluation of the association between markers of immune function and degree of HIV viral suppression and vasomotor symptoms, and also the degree of anxiety and depressive symptoms in larger studies of HIV-infected women in the perimenopause and postmenopausal phase.
CONCLUSIONS
Our data demonstrate that perimenopausal HIV-infected women experience a disproportionate rate of affective symptom burden, particularly depressive symptoms, compared with non-HIV-infected women during 12 months of follow-up. Furthermore, we found that vasomotor symptoms, specifically hot flash severity, which was increased in HIVinfected women compared with non-HIV-infected women, were also associated with anxiety and depressive symptoms in our cohort. The simultaneous occurrence of increased vasomotor and affective symptoms among HIV-infected women at midlife has potential to further compromise a variety of social and clinical factors including quality of life and adherence to antiretroviral therapy. For this reason, it is imperative for clinicians caring for HIV-infected women in the perimenopause transition, to assess for new onset, persistent, or increased presence of mood symptoms or anxiety, and consider initiating or adjusting current treatment regimens for affective symptoms, to prevent negative implications on the overall health and well being of this population. To this end, traditional barriers to psychological screening, including diffusion of responsibility among clinicians, uncertainly about how to manage elevated scores on screening instruments, and lack of referral sources, need to be addressed, and systems put in place to support clinicians in their effort to provide comprehensive care to the growing number of HIV-infected women at midlife.
